HFE genotype in patients with hemochromatosis and other liver diseases with iron overload in the Czech Republic;Mutace v genu HFE u nemocných s hereditární hemochromatózou a dalšími chorobami s akumulací železa v játrech

Ceska a Slovenska Gastroenterologie a Hepatologie

Volumn 56, Issue 6, 2002, Pages 214-219

  Putova I ^a   Cimburova M ^a   Cieslarova B ^a   Pucelikova T ^a   Stransky J ^a   Horak J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CHRONIC HEPATITIS; CZECH REPUBLIC; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HEMOCHROMATOSIS; HOMOZYGOTE; HUMAN; IRON ABSORPTION; IRON OVERLOAD; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; SMALL INTESTINE;

EID: 0036963631     PISSN: 1213323X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Niderau, C., Fischer, R., Sonneberg, A. et al. Survival and causes of death in cirrhotic and in non-cirrhotic patients with primary haemochromatosis. New Engl. J. Med., 1985, 313, s. 1256.
2. Žd'árský, E., Horák, J., Stříteský, J., Heirler, F. Stanovení frekvence C282Y mutace pro populaci České republiky a citlivá detekce hemochromatózy z Guthrie karet. Čas. Lékařů Českých, 1999, 138, č. 16, s. 497-499.
3. Feder, J. N., Gnirke, A., Thomas, W., et al. A novel MHC class I - like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet., 1996, 13, s. 339-345.
4. Feder, J. N., Tsuchihashi, Z., Irrinki, A., et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J. Biol. Chem., 1997, 272, s. 14025-14028.
5. Waheed, A., Parkkila, S., Zhou, X. Y., et al. Hereditary haemochromatosis: Effects of C282Y and H63D mutations on association with beta 2 - microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS - 7 cells. Proc. Natl. Acad. Sci., USA, 1997, 94, s. 12384-12389.
6. Feder, J. N., Penny, D. M., Irrinki, A., et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Nat. Acad. Sci., 1998, 95, s. 1472-1477.
7. Mura, C., Raguenes, O., Ferec, C. HFE mutation analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood, 1999, roč. 93, č. 8, s. 2502-2505.
8. Barton, J. C., Sawada-Hirai, R., Rothenberg, B. E., Acton, R. T. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Molec. Dis., 1999, roč. 25, s. 146-154.
9. Piperno, A., Arosio, C., Fossati, L., et al. Two novel nonsense mutations of HFE gene in five unrelated italian patients witth hemochromatosis. Gastroenterology, 2000, roč. 119, č. 2, s. 441-445.
10. Wallace, D. F., Doooley, J. S., Walker, A. P. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology, 1999, roč. 116, s. 1409-1412.
11. Datz, C., Lalloz, M. R. A., Vogel, W., et al. Predominance of the HLA - H Cys282Tyr mutation in Austrian patients with genetic harmochromatosis. J. Hepatol., 1997, roč. 27, s. 773-779.
12. Niederau, C., Niederau, C. M., Lange, S., et al. Screening for haemochromatosis and iron deficiency in employees and primary care patients in western Germany. Ann. Intern. Med., 1998, roč. 128, s. 337-345.
13. Bulaj, Z. J., et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. New Engl. J. Med., 1996, 335, s. 1799-1805.
14. Tracey, A. Hereditary Hemochromatosis. JAMA, 1993, 269, s. 3152-3154.
15. Bonkovsky, H. L., et al. Iron in liver deseases other than hemochromatosis. Sem. Liver Dis., 1996, roč. 16, s. 65-82.
16. Farinati, F., et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol., 1995, roč. 22, č. 4, s. 449-456.
17. Roberts, A. G., et al. The frequency of hemochromatosis - associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology, 1997, roč. 25, s. 159-161.
18. Bradley, L. A., Haddow, J. E., Palomaki, G. E. Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands. J. Med. Screen., 1996, roč. 3, č. 4, s. 171-177.
19. Bradley, L. A., Johnson, D. D., Haddow, J. E., Palomaki, G. E., Robertson, N. H. Hereditary haemochromatosis mutation frequencies in the general population. J. Med. Screen., 1998, roč. 5, č. 1, s. 34-36.
20. Merryweather-Clarke, A. T., Pointon, J. J., Shearman, J. D., Robson, K. J. Global prevalence of putative haemochromatosis mutations. J. Med. Genet., 1997, roč. 34, s. 275-278.
21. Powell, L. W., Yapp, T. R. Hemochromatosis. Clin. Liver Dis., 2000, roč. 4, č. 1, s. 211-228.
22. Powell, L. W., George, D. K., McDonnell, S. M., Kowdley, K. V. Diagnosis of hemochromatosis. Ann. Intern. Med., 1998, roč. 129, č. 11, s. 925-931.
23. Olynyk, J. K., Cullen, D. J., Aquilia, S., Rossi, E., Summerville, L., Powell, L. W. A population-based study of the clinical expression of the hemochromatosis gene. N. Engl. J. Med., 1999, 341, č. 10, s. 718-724.
24. Tracey, A. Hereditary Hemochromatosis. JAMA, 1993, 269, s. 3152-3154.
25. Fiel, M. I., Schiano, T. D., Guido, M., et al. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. Am. J. Clin. Pathol., 2000, roč. 113, č. 1, s. 35-39.
26. Casaril, M., Stanzial, A. M., Tognella, P., et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepato-gastroenterology, 2000, roč. 47, s. 220-225.
27. Graudal, N., Milman, N., Galloe, A. M., Christoffersen, P. Distribution of liver haemosiderin iron in 187 patients with various types of hepatic diseases. APMIS, 1996, roč. 104, č. 3, s. 220-226.
28. Houglum, K., Ramm, G. A., Crawford, D. H., Witztum, J. L., Powell, L. W., Chojkier, M. Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatology, 1997, roč. 26, č. 3, s. 605-610.
29. Valerio, L. G. Jr., Petersen, D. R. Characterization of hepatic iron overload following dietary administration of dicyclopentadienyl iron (Ferrocene) to mice: cellular, biochemical, and molecular aspects. Exp. Mol. Pathol., 2000, roč. 68, č. 1, s. 1-12.
30. Zhao, M., Laissue, J. A., Zimmermann, A. Hepatocyte apoptosis in hepatic iron overload diseases. Histol. Histopathol., 1997, roč. 12, č. 2, s. 367-374.
31. Chapoutot, C., Esslimani, M., Joomaye, Z., et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut, 2000, roč. 46, č. 5, s. 711-714.